Cepheid is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems and tests for genetic analysis in the clinical, industrial, and biothreat markets. The company's systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company's easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification, and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. Cepheid previously traded under the ticker NASDAQ: CPHD.
Missing: Cepheid's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
ESPs containing Cepheid
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
Point-of-care (POC) testing refers to diagnostic lab tests that can be performed rapidly, reliably, and easily at or near the point of care. Starting with a biological sample, POC tests detect or quantify certain analytes ‚Äî such as infectious agents, cardiac markers, and blood glucose ‚Äî to inform clinical decision making.
Missing: Cepheid's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Cepheid
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Cepheid is included in 3 Expert Collections, including Omics.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Health Monitoring & Diagnostics
Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting
Cepheid has filed 1 patent.
Technical drawing, Honeycombs (geometry), Architecture, Structural geology, Physical oceanography
Technical drawing, Honeycombs (geometry), Architecture, Structural geology, Physical oceanography
Latest Cepheid News
Nov 18, 2022
Save for later Foundation Medicine FoundationReport+ Foundation Medicine has launched FoundationReport+, a new interactive digital report intended to aid users in their interaction with the company's comprehensive genomic profiling (CGP) results. Accessible through the Foundation Medicine online portal, the new digital reporting tool is customizable to user preference and allows healthcare providers to control the depth of information they would like to see. As an adaptable system, the reporting platform has the potential to evolve in reflection of changes in clinical practice, the company said. Cepheid Xpert GBS LB XC and Xpert Xpress MVP Cepheid has launched its Xpert GBS LB XC test to qualitatively detect Group B Streptococcus (GBS) from enriched Lim broth cultures of patient samples. The new assay builds on Cepheid's previous Xpert GBS LB test launched in 2012 by adding another target. The new molecular test includes dual targets in highly conserved regions of the GBS genome to improve coverage and performance, Cepheid said in a statement. The test can provide positive results in 27 minutes and negative results in 43 minutes. Cepheid has also launched its Xpert Xpress MVP test, a multiplexed PCR test to detect DNA from organisms associated with bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis from a single vaginal swab sample. The test returns results in an hour and runs on Cepheid's GeneXpert systems. Thermo Fisher Scientific Rapid RT-PCR Accula Flu A/Flu B Test Thermo Fisher Scientific has released the RT-PCR Accula Flu A/Flu B Test, a rapid, point-of-care RT-PCR test that enables healthcare providers to detect and differentiate influenza A and B in about 30 minutes. The test runs on the palm-sized, portable Accula Dock, which plugs into a standard wall outlet to enable RT-PCR testing without the need for a specialized laboratory, the company said. Thermo Fisher acquired Mesa Biotech, the company that developed and commercialized the Accula platform, in 2021. The Accula Dock and Accula Flu A/Flu B test received 510(k) clearance and CLIA waived status in 2018 from the US Food and Drug Administration. Olink Flex Olink has launched its Flex product, which allows researchers to create custom panels measuring up to 21 human proteins with absolute quantification. Users can select prevalidated assays from a catalogue spanning more than 200 human protein biomarkers covering biological pathways including inflammation, immuno-oncology and oncology, neurology, and cardiovascular disease. Flex panels are compatible with Olink's Signature Q100 instrument. Juno Diagnostics Juno Hazel Juno Diagnostics has launched Juno Hazel, a noninvasive prenatal screening test that uses blood from a finger prick. The assay makes use of JunoDx's proprietary sample collection kit and does not require phlebotomy. It tests for common chromosomal aneuploidies, including trisomy 21, 18, and 13, and promises greater than 99 percent sensitivity and specificity. Cytek Biosciences Cytek Cloud Cytek Biosciences has launched Cytek Cloud, a cloud-based platform that features two integrated tools (Panel Builder and Experiment Builder) to streamline workflows on Cytek's cell sorters and analyzers including Northern Lights, Aurora, and Aurora CS. Cytek Cloud combines all of Cytek's spectral panel design tools in one place and enables users to prepare experiments remotely prior to accessing the instrument. Sony SFA – Life Sciences Cloud Platform Sony has launched the SFA – Life Sciences Cloud Platform, cloud-based flow cytometry data analysis software that can perform a wide array of analysis protocols from conventional analyses like gating to advanced analyses such as dimensionality reduction. The platform is compatible with Sony's flagship ID7000 spectral cell analyzer, which can deliver streamlined multicolor cell analysis with more than 44 colors, Sony said. Raw data output and analysis results from the ID7000 software can be directly imported and analyzed without any conversion. In addition, the new product features BL-FlowSOMiv, a newly developed algorithm that speeds up FlowSOM, one of the clustering methods, Sony said. MRC Holland SALSA Digital MLPA Probemixes for Multiple Myeloma and Acute Lymphoblastic Leukemia MRC Holland has launched two new research-use-only assays for hematological malignancies: SALSA Digital MLPA Probemix D006 Multiple Myeloma and SALSA DigitalMLPA Probemix D007 Acute Lymphoblastic Leukemia. The multiple myeloma panel targets all non-acrocentric chromosomal arms to enable the detection of large copy number alterations and ploidy changes. Chromosomal regions that are frequently altered in multiple myeloma, including 1q, 1p, 13q, and 17p, are especially well-covered, allowing for high-resolution screening of these arms. The assay also covers genes of emerging significance, such as BCMA and GPRC5D, MRC Holland said. The ALL assay has been specifically developed to increase the genomic coverage of ALL-related regions, making it possible to include all the targets from ALL-relevant SALSA MLPA Probemixes and more in one assay. A single reaction is enough to simultaneously screen for numerous ALL-related alterations, such as intragenic copy number alterations (e.g. IKZF1del), aneuploidies (e.g. 5q deletion), whole chromosome gains, losses and amplifications (e.g. iAMP21), gross ploidy changes (e.g. high hyperdiploidy), and intrachromosomal gene fusions (e.g. STIL-TAL1 fusion), the company said. In addition, this panel includes probes that target subtelomeric, pericentromeric, and middle regions of most chromosomal arms. This allows the detection of larger copy number alterations and ploidy status (hyperdiploidy and hypodiploidy). Both panels are based on MRC Holland's SALSA DigitalMLPA technology, which merges the MLPA method with next-generation sequencing. Both assays are available worldwide, a company spokesperson said. MGI Tech MGISP-Smart 8 Automated Sample Preparation System MGI Tech has released the MGISP-Smart 8 automated sample preparation system in Europe. MGISP-Smart 8 is an eight-channel pipetting robot capable of independent multi-channel positioning and dual-level liquid detection, according to MGI. Equipped with technologies such as an intelligent integrated gripper and triple slide track design, the instrument enables a variety of applications, including sequencing library preparation to nucleic acid detection and sample preparation. Bio-Rad Molecular Blood Screening Controls for HBV, HCV, and HIV-1 Bio-Rad Laboratories said this week that its Exact Diagnostics HBV, HCV, and HIV-1 Screen Controls are now available to laboratories in Europe after having received CE IVD marking earlier this year. These controls are designed to monitor the performance of blood donor screening assays, including extraction, amplification, and detection, and are calibrated against WHO International Standards for HBV, HCV, and HIV-1. The products are made of whole viruses in a high-quality citrate plasma matrix to ensure lot-to-lot reproducibility, have an 18-month shelf life from date of manufacture (when stored at -20° C or below), and have a 24-hour stability (when stored at 2-8° C). Sentinel Diagnostics SentiNat 200 System, Stat-Nat SN200 Assays Sentinel Diagnostics has launched the fully automated SentiNat 200 sample-to-result system and Stat-Nat SN200 real-time PCR assays to quantitatively detect 10 viruses. According to the Milan, Italy-based firm, the products are for midsized to large laboratories that diagnose viral infections. SentiNat 200 is a compact platform for DNA/RNA extraction, PCR setup, and amplification. It contains two integrated thermal cyclers and FastFinder analysis software and can be used to perform a multiparametric analysis of up to 15 viruses in one run, Sentinel said, adding the assay can process as many as 48 samples in four hours. PCR Biosystems Clara qPCR Reagent Mixes PCR Biosystems has launched three Clara qPCR reagent mixes: Clara Probe Mix, Clara Probe 1-Step Mix, and Clara HRM. The Clara Probe Mix is a concentrated 4x mix for single and multiplex assays that enables detection of DNA targets down to 1 pg/ml of cDNA. The mix can be used for melt-curve analysis and is available in No-ROX, Lo-ROX, Hi-ROX, and separate-ROX options. The Clara Probe 1-Step Mix is a single tube 4x RT-qPCR mix for universal probe-based detection of RNA and DNA targets in single and multiplex assays. The Clara HRM Mix uses SyGreen 2 dye with a 2x qPCR mix and can be used to detect genetic mutations, identify genotypes based on SNPs, or calculate percent methylation of a target region. It is compatible with many standard qPCR thermocyclers. For more new products and services, please visit the New Products page on our website.
Cepheid Web Traffic
Cepheid Frequently Asked Questions (FAQ)
When was Cepheid founded?
Cepheid was founded in 1996.
Where is Cepheid's headquarters?
Cepheid's headquarters is located at 904 Caribbean Drive, Sunnyvale.
What is Cepheid's latest funding round?
Cepheid's latest funding round is Grant.
How much did Cepheid raise?
Cepheid raised a total of $60.7M.
Who are the investors of Cepheid?
Investors of Cepheid include U.S. Department of Health and Human Services, Danaher, Medtronic, Invemed Associates, Fujirebio and 9 more.
Who are Cepheid's competitors?
Competitors of Cepheid include Visby Medical, Cardea Bio, Baebies, MeMed, Accellix, Inflammatix, Oxford Nanopore Technologies, LumiraDx, Cue Health, Roche Holding and 24 more.
Compare Cepheid to Competitors
Cardea Bio is a mass producer of biocompatible semiconductors, also called the BPU™ (Biosignal Processing Unit). The BPU is a semiconductor capable of translating real-time streams of multiomics signals into digital information. Through the BPU™ platform, Cardea's long-term vision is to democratize access to the biosignals and insights behind the most advanced technology on the planet: nature and biology. Cardea Bio was founded in 2013 and is based in San Diego, California.
Hemex creates affordable, life-changing medical diagnostics for under-served people everywhere. Its diagnostic platform is designed to reach populations at risk for malaria and sickle cell disease.
Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.
Genalyte transforms the doctor-patient relationship by providing rapid diagnostic testing right in the doctor's office. The company's technology delivers results to physicians in minutes from just a single drop of blood, yielding better outcomes for the patient, empowering doctors to be more effective, and creating a more efficient healthcare system.
Visby Medical is transforming the order of diagnosis and treatment for infectious diseases so clinicians can test, talk with, and treat the patient in a single visit. The company’s technology development program culminated in an instrument-free, single-use PCR platform that rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. Visby Medical technology also offers the Visby Medical COVID-19 Test, and its robust pipeline includes tests for other infectious diseases. It was founded in 2015 and is based in San Jose, California.
Ellume is a digital diagnostics company that develops and commercializes connected products for healthcare professionals and consumers. The company has developed a new biosensor technology that features unique optoelectronics and biologics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.